Baxter International (NYSE:BAX) Share Price Crosses Below Fifty Day Moving Average - Should You Sell?

Key Points

• Baxter shares fell below their 50-day moving average, trading as low as $23.37 versus the $24.65 average, signaling near-term technical weakness.
• The company’s third-quarter results beat expectations, with adjusted EPS of $0.58 and revenue of $2.98 billion, while management raised its full-year 2026 earnings outlook and maintained the quarterly dividend.
• Despite the earnings beat, EPS declined from $0.69 a year earlier, and margin pressure and a negative net margin remain concerns. Analysts’ consensus rating is “Reduce,” with an average price target of $22.27.

Baxter International Inc. (NYSE:BAX - Get Free Report) crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $24.65 and traded as low as $23.37. Baxter International shares last traded at $23.4770, with a volume of 15,668,814 shares.

More Baxter International News

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Baxter reported third-quarter adjusted earnings of $0.58 per share, above analysts’ estimates of approximately $0.51–$0.52, while revenue reached $2.98 billion versus the $2.91 billion consensus. Sales increased 5% from the prior year. Baxter International Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management raised its full-year 2026 earnings outlook, citing broad-based segment growth despite ongoing margin pressure. The improved guidance is a positive signal for future earnings and cash generation. Baxter Q3 Earnings Beat on Broad-Based Growth, 2026 Outlook Raised
• Positive Sentiment: Baxter declared its quarterly dividend alongside the results, maintaining shareholder returns while reporting a profitable quarter. Baxter Raises 2026 Guidance and Declares Quarterly Dividend
• Neutral Sentiment: The earnings call and financial schedules provide additional detail on segment performance, the updated outlook and the company’s plans to address margin pressure. Baxter Q3 2026 Earnings Call Transcript
• Negative Sentiment: Although earnings exceeded expectations, quarterly EPS fell from $0.69 a year earlier to $0.58. Continued margin pressure and Baxter’s negative net margin remain concerns for investors. Baxter Reports Third-Quarter Results

Wall Street Analyst Weigh In

BAX has been the topic of a number of research analyst reports. Stifel Nicolaus raised their target price on Baxter International from $19.00 to $24.00 and gave the company a "hold" rating in a report on Tuesday, July 28th. Weiss Ratings lowered Baxter International from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday, October 8th. Wolfe Research started coverage on shares of Baxter International in a research note on Tuesday, October 20th. They issued a "peer perform" rating for the company. Jefferies Financial Group reissued a "hold" rating and set a $25.00 target price on shares of Baxter International in a research report on Thursday. Finally, Wall Street Zen lowered shares of Baxter International from a "buy" rating to a "hold" rating in a research note on Saturday, October 10th. One analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Baxter International has a consensus rating of "Reduce" and an average target price of $22.27.

Baxter International Price Performance

The stock has a market cap of $12.14 billion, a P/E ratio of -11.34, a price-to-earnings-growth ratio of 3.85 and a beta of 0.65. The firm has a 50-day moving average price of $24.65 and a 200-day moving average price of $21.35. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.32 and a current ratio of 1.95.

Baxter International (NYSE:BAX - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.06. The firm had revenue of $2.98 billion during the quarter, compared to the consensus estimate of $2.91 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%. The company's revenue was up 5.0% on a year-over-year basis. During the same period last year, the company earned $0.69 earnings per share. On average, analysts forecast that Baxter International Inc. will post 2.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Baxter International

Several institutional investors and hedge funds have recently bought and sold shares of BAX. CX Institutional raised its holdings in shares of Baxter International by 2.3% during the 3rd quarter. CX Institutional now owns 19,858 shares of the medical instruments supplier's stock worth $477,000 after acquiring an additional 448 shares in the last quarter. Baird Financial Group Inc. raised its stake in shares of Baxter International by 1.1% during the second quarter. Baird Financial Group Inc. now owns 44,722 shares of the medical instruments supplier's stock valued at $953,000 after acquiring an additional 476 shares in the last quarter. North Dakota State Investment Board lifted its position in shares of Baxter International by 3.3% in the 3rd quarter. North Dakota State Investment Board now owns 15,735 shares of the medical instruments supplier's stock worth $378,000 after purchasing an additional 500 shares during the period. CWA Asset Management Group LLC grew its stake in Baxter International by 5.0% in the third quarter. CWA Asset Management Group LLC now owns 12,617 shares of the medical instruments supplier's stock valued at $303,000 after purchasing an additional 599 shares during the last quarter. Finally, Empirical Finance LLC boosted its position in shares of Baxter International by 3.5% in the 2nd quarter. Empirical Finance LLC now owns 18,170 shares of the medical instruments supplier's stock worth $387,000 after purchasing an additional 608 shares in the last quarter. 90.19% of the stock is currently owned by hedge funds and other institutional investors.

Baxter International Company Profile

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter's portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.